AT148307B - X-ray contrast media. - Google Patents

X-ray contrast media.

Info

Publication number
AT148307B
AT148307B AT148307DA AT148307B AT 148307 B AT148307 B AT 148307B AT 148307D A AT148307D A AT 148307DA AT 148307 B AT148307 B AT 148307B
Authority
AT
Austria
Prior art keywords
ray contrast
contrast media
pyridones
ray
substituted
Prior art date
Application number
Other languages
German (de)
Original Assignee
Ig Farbenindustrie Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ig Farbenindustrie Ag filed Critical Ig Farbenindustrie Ag
Application granted granted Critical
Publication of AT148307B publication Critical patent/AT148307B/en

Links

Description

  

   <Desc/Clms Page number 1> 
 
 EMI1.1 
 



   Es ist bekannt, dass jodenthaltende Verbindungen vielfach Röntgenkontrastmittel sind, die für die röntgenographische Darstellung von Organen, besonders auch der Harnwege, von Bedeutung sind. 



   Das Bestreben der Technik geht nun dahin, durch Steigerung der Jodkonzentration eine Vertiefung des Röntgenschattens zu erzielen. Man hat deshalb schon 2-Pyridone mit hohem Jodgehalt dargestellt. Derartige Verbindungen zeigten aber als Röntgenkontrastmittel gegenüber den monojodsubstituierten 2-Pyridonen keine Vorzüge, da die Einführung eines zweiten Jodatoms die Löslichkeit ausserordentlich herabsetzt, so dass die intravenöse Darreichung sich als unmöglich erwies. 



   Es wurde gefunden, dass 3.5-Dihalogen-4-pyridone, die am Stickstoff durch eine zur Salzbildung befähigte saure oder basische Gruppe substituiert sind, in Form ihrer Salze mit Basen oder Säuren sehr viel leichter in Wasser löslich sind als die entsprechenden 2-Pyridone und deshalb ausgezeichnet für die röntgenographisehe Darstellung von Hohlsystemen des Körpers, z. B. zur Darstellung der Harnwege, verwendbar sind. Die am Stickstoff durch eine zur Salzbildung befähigte saure oder basische Gruppe substituierten 3.5-Dihalogen-4-pyridone zeichnen sich durch bemerkenswerte Ungiftigkeit aus. Sie können nach dem im Patent Nr. 145823 beschriebenen Verfahren hergestellt werden. 



   Beispiel : Bei der röntgenographischen Darstellung der Harnwege eines Hundes zeigte sich z. B., wenn einem Hunde von 26 kg 10 g 3.5-Dijod-4-pyridon-N-essigsaures Natrium intravenös verabreicht werden, dass der Harn des Tieres von der ersten bis zur fünften Stunde nach der Injektion etwa   5'3%   organisch gebundenes Jod gegenüber einem maximalen Gehalt von etwa   2'5%   nach Verabreichung der entsprechenden Monojodverbindung enthält. Infolgedessen ist die erzielte Röntgenkontrastwirkung etwa doppelt so stark, so dass sich sehr gute Röntgenbilder von den Harnwegen auf diese Weise herstellen lassen. 

**WARNUNG** Ende DESC Feld kannt Anfang CLMS uberlappen**.



   <Desc / Clms Page number 1>
 
 EMI1.1
 



   It is known that iodine-containing compounds are often X-ray contrast media which are important for the X-ray imaging of organs, especially the urinary tract.



   The endeavors of the technology are now to achieve a deepening of the X-ray shadow by increasing the iodine concentration. For this reason, 2-pyridones with a high iodine content have already been presented. However, such compounds showed no advantages as X-ray contrast media compared to the monoiodine-substituted 2-pyridones, since the introduction of a second iodine atom extremely reduces the solubility, so that intravenous administration proved impossible.



   It has been found that 3,5-dihalo-4-pyridones, which are substituted on the nitrogen by an acidic or basic group capable of salt formation, are much more readily soluble in water in the form of their salts with bases or acids than the corresponding 2-pyridones and therefore excellent for the radiographic representation of hollow systems of the body, e.g. B. to represent the urinary tract, can be used. The 3,5-dihalo-4-pyridones substituted on the nitrogen by an acidic or basic group capable of salt formation are notable for their remarkable non-toxicity. They can be made by the process described in Patent No. 145823.



   Example: The radiographic representation of a dog's urinary tract showed, for example, For example, if 10 g of 3.5-diiodo-4-pyridone-N-acetic acid sodium are administered intravenously to a dog weighing 26 kg, the urine of the animal will have about 5'3% organically bound iodine from the first to the fifth hour after the injection compared to a maximum content of about 2'5% after administration of the corresponding monoiodine compound. As a result, the X-ray contrast effect achieved is about twice as strong, so that very good X-ray images of the urinary tract can be produced in this way.

** WARNING ** End of DESC field may overlap beginning of CLMS **.

 

Claims (1)

PATENT-ANSPRUCH : Röntgenkontrastmittel, dadurch gekennzeichnet, dass am Stickstoff durch eine zur Salzbildung befähigte saure oder basische Gruppe substituierte 3.5-Dihalogen-4-pyridone als Kontrastmittel Verwendung finden. **WARNUNG** Ende CLMS Feld Kannt Anfang DESC uberlappen**. PATENT CLAIM: X-ray contrast medium, characterized in that 3,5-dihalogeno-4-pyridones substituted on the nitrogen by an acidic or basic group capable of salt formation are used as contrast medium. ** WARNING ** End of CLMS field may overlap beginning of DESC **.
AT148307D 1930-12-20 1931-12-19 X-ray contrast media. AT148307B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE148307T 1930-12-20

Publications (1)

Publication Number Publication Date
AT148307B true AT148307B (en) 1937-01-11

Family

ID=29278143

Family Applications (1)

Application Number Title Priority Date Filing Date
AT148307D AT148307B (en) 1930-12-20 1931-12-19 X-ray contrast media.

Country Status (1)

Country Link
AT (1) AT148307B (en)

Similar Documents

Publication Publication Date Title
DE3038853A1 (en) NEW N-HYDROXY-ALKYLATED DICARBONIC ACID-BIS- (3,5-DICARBAMOYL-2,4,6-TRIJODANILIDES), THEIR PRODUCTION AND THEIR CONTAINING X-RAY CONTRAST AGENTS (II)
CH414063A (en) X-ray contrast media
DE1192369B (en) X-ray contrast media
AT148307B (en) X-ray contrast media.
DE646116C (en) Contrast media for the roentgenological visualization of hollow systems of the body
DE1922578C3 (en) 4,7,10-trioxatrldecane-1,13-dioyibis- (3-carboxy-2,4,6-triiodo-anilide) and its salts, processes for the preparation of these compounds and X-ray contrast media containing these compounds
AT134007B (en) Radiological procedure.
AT155477B (en) Process for the production of water-soluble calcium double compounds of ascorbic acid.
AT136142B (en) Radiological procedure.
AT128587B (en) Radiological procedure.
AT128571B (en) Process for the preparation of agents with anesthetic effect.
AT52846B (en) Process for the preparation of bromine diethyl acetylurea.
AT210565B (en) X-ray contrast media
AT41282B (en) Process for the preparation of silver protein photographic light-sensitive emulsions.
AT286494B (en) X-ray contrast media
AT22733B (en) Process for the production of ferrous fertilizers and animal feed.
AT89921B (en) Process for the preparation of an oxyphenylquinolinedicarboxylic acid and its derivatives.
AT325762B (en) X-RAY CONTRAST AGENT
AT289769B (en) Process for the preparation of the new 4,7,10,13-tetraoxahexadecane-1,16-diacid-bis- (3&#39;carboxy-2 &#39;, 4&#39;, 6&#39;-triiodanilide) and its salts
DE944953C (en) Process for the preparation of a therapeutic agent consisting of the calcium salt of Ca-ethylene diamine tetraacetic acid
DE1937211C3 (en) 4,7,10,13-Telraoxahexadecan-i, 16dioyl-bis- (3-carboxy-2,4,6-triiodo-anilide) and its salts, processes for the preparation of these compounds and X-ray contrast media containing these compounds
AT51805B (en) Process for the production of durable, solid perborate mixtures from sodium perborate and a solid acid salt, which develop hydrogen peroxide with water.
AT119480B (en) Process for the preparation of addition compounds of sulfur dioxide with aromatic p-diamines.
DE637792C (en) Process for the production of durable solutions of complex lead salts
AT97145B (en) Process for the preparation of mercury salts of complex bismuthic acids.